Since that discovery, inhibition of androgen receptor (AR) function through androgen deprivation (ADT) and direct AR inhibition has remained the mainstay of treatment.1,2 The current treatment paradigm for metastatic PCa is to treat men with ADT in combination with AR signaling inhibitors (ARSI) or chemotherapy until disease progression. The gene discussed is AR; the disease is posterior cortical atrophy.